Autopsy report · NCT00739609

IDO Inhibitor Study for Relapsed or Refractory Solid Tumors

“Lack of enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 2 months before it stopped.
• 17 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

NewLink Genetics Corporation

Sponsor type

Industry

Conditions

Breast Cancer; Lung Cancer; Melanoma; Pancreatic Cancer; Solid Tumors

Interventions

1-methyl-D-tryptophan

Participants

17

Sites

1

Countries

United States

Trials that died the same way

• A Post Market Study on DRG Stimulation in FBSS (SYMPATHY)
  “Lack of enrollments” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.